GlaxoSmithKline Seeks Increased Damages in Teva Pharmaceuticals Labeling Dispute

GlaxoSmithKline LLC is pressing a Delaware federal judge to enhance the $235 million damages award that was previously granted against Teva Pharmaceuticals USA Inc. by a jury in 2017. The case involved infringement related to the “skinny” labeling of a pharmaceutical product, and it has returned to district court for further consideration. This significant legal development highlights ongoing complexities in labeling disputes within the pharmaceutical industry. For more detailed insights, you can read the original coverage here.